After SpringWorks Therapeutics (SWTX) pre-announced Q4 U.S. Ogsiveo sales of $61.5M, TD Cowen noted that this was above the firm’s $57.0M estimate and consensus of $59.8M. However, the firm thinks the stock could be weak today as “some were hoping for an announcement of a takeout.” With two fully owned drugs globally and profitability seen in the first half of FY26, the firm does anticipate that SpringWorks “could be a takeout with time as the value of both assets becomes clearer to strategics,” added the analyst, who has a Buy rating and $63 price target on the shares.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- SpringWorks Therapeutics Reports Strong 2024 Financial Results
- SpringWorks Therapeutics sees Q4 U.S. OGSIVEO net revenue $61.5M
- SpringWorks Therapeutics rumor highlighted in Betaville alert
- Biotech Alert: Searches spiking for these stocks today
- SpringWorks Therapeutics price target lowered to $78 from $80 at Guggenheim